Source link : https://www.newshealth.biz/health-news/novel-drug-for-rare-chronic-liver-disease-wins-conditional-fda-approval/
The FDA granted accelerated approval to oral elafibranor (Iqirvo) for treating primary biliary cholangitis (PBC) in adults, drugmaker Ipsen announced on Monday. A first-in-class dual peroxisome proliferator-activated receptor (PPAR) agonist, elafibranor is indicated in combination with ursodeoxycholic acid (UDCA) for patients with an inadequate response to UDCA, or as monotherapy for those unable to tolerate […]
Author : News Health
Publish date : 2024-06-11 15:09:58
Copyright for syndicated content belongs to the linked Source.
Categories